Lisa joined Alvogen in 2010 and serves as the CEO of Alvogen’s business. She has worked in various leadership roles in the pharmaceutical industry for the past 20 years. Her background in patent and regulatory strategy has been a key ingredient in Alvogen’s success. Lisa’s own intellectual property strategy led to the company’s launch of the first generic Tamiflu following a successful compound patent challenge. Under Lisa’s leadership, her team has launched a number of challenging first to market products, such as generic Exelon patch and generic Suboxone film. As the generic market has transformed in recent years, Lisa’s commercial acumen and strategic insight have allowed Alvogen’s U.S. business to thrive.
Lisa holds her Juris Doctorate from Case Western University and an Honors Bachelor of Science degree from Lakehead University.